0001104659-20-138756.txt : 20201222 0001104659-20-138756.hdr.sgml : 20201222 20201222203914 ACCESSION NUMBER: 0001104659-20-138756 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201222 FILED AS OF DATE: 20201222 DATE AS OF CHANGE: 20201222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Werner Milton H. CENTRAL INDEX KEY: 0001827621 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39676 FILM NUMBER: 201409525 MAIL ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc. CENTRAL INDEX KEY: 0001750149 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 678-392-3419 MAIL ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 3 1 tm2034420d1_form3.xml FORM 3 X0206 3 2020-12-22 0 0001750149 Inhibikase Therapeutics, Inc. IKT 0001827621 Werner Milton H. 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 1 1 1 0 President and CEO Common Stock 5244938 D Stock Option (right to buy) 0.38 2011-06-01 2021-06-01 Common Stock 43707 D Stock Option (right to buy) 2.02 2023-06-01 Common Stock 21853 D Stock Option (right to buy) 2.02 2025-03-01 Common Stock 21853 D Stock Option (right to buy) 2.31 2025-11-01 Common Stock 21853 D Stock Option (right to buy) 2.31 2026-11-01 Common Stock 21853 D Stock Option (right to buy) 2.31 2027-11-01 Common Stock 21853 D Stock Option (right to buy) 4.79 2028-11-01 Common Stock 21853 D Stock Option (right to buy) 5.57 2029-11-01 Common Stock 21853 D The number of shares has been adjusted to reflect a one-for-1.14396 reverse stock split of the Issuer's common stock effected on August 24, 2020 (the "Reverse Split"). The number of shares has been adjusted to reflect the Reverse Split and excludes fractional shares resulting from the Reverse Split, which shall be paid in cash upon exercise. The exercise price has been adjusted to reflect the Reverse Split. The option vested in twelve equal monthly installments beginning on June 1, 2013. The option vested in twelve equal monthly installments beginning on March 1, 2015. The option vested in twelve equal monthly installments beginning on November 1, 2015. The option vested in twelve equal monthly installments beginning on November 1, 2016. The option vested in twelve equal monthly installments beginning on November 1, 2017. The option vested in twelve equal monthly installments beginning on November 1, 2018. The option vested in twelve equal monthly installments beginning on November 1, 2019. /s/ Milton H. Werner 2020-12-22